Amgen Inc. (United States) holds 6 active US FDA Type II Drug Master Files and 1 inactive and is linked to 7 FDA-registered manufacturing sites. 24 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Amgen Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/amgen-inc
Overview
Amgen Inc. is a leading biotechnology company that develops innovative therapies for serious illnesses. It focuses on areas of high unmet medical need and leverages its expertise in molecular biology and genetics to discover, develop, and deliver innovative human therapeutics.
Therapeutic areas
API / Drug Master Files
Amgen Inc. holds 6 active (7 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- AMG 157 (TEZEPELUMAB) PHASE 3 CMC AMENDMENT (DRUG SUBSTANCE AND DRUG PRODUCT)Active2017-08-21
- INTRAVENOUS SOLUTION STABILIZER (IVSS)Active2017-04-20
- AMG 282 DRUG SUBSTANCEActive2016-02-22
- AMG 191 DRUG SUBSTANCEActive2015-11-06
- AMG 191 CELL LINE DEVELOPMENTActive2015-11-06
- AMG 191 DRUG PRODUCTActive2015-11-06
- HUMAN MONOCLONAL ANTIBODY (MDX-015)(SP2/0,- AG14 CELLS, MEDAREX) TO IL15Inactive2001-04-02
Registered manufacturing sites (7)
Physical sites registered with the US FDA and resolved to Amgen Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
- Amgen Europe BVNBNT, Netherlands · Analytical testing · LabellingSite GMP match
- Amgen Inc.Louisville, United States · Labelling · Packaging
- Amgen Manufacturing Limited LLCJuncos, United States · API manufacture
- Amgen Singapore Manufacturing Pte. Ltd.Singapore, Singapore · API manufactureSite GMP match
- Amgen Technology (ireland) Unlimited CompanyDun Laoghaire, Ireland · Analytical testing · LabellingSite GMP match
- Amgen, IncThousand Oaks, United States · API manufacture
- Immunex Rhode Island CorporationWest Greenwich, United States · API manufacture
FDA compliance signals
24 FDA enforcement records linked to this company.
- warning_letter2026-08-12
FDA Warning Letter (drug product)
- recall — Class II2026-07-01
CGMP Deviations
- recall — Class II2026-07-01
CGMP Deviations
- recall — Class II2026-07-01
Presence of Foreign Substance.
- recall — Class II2026-07-01
CGMP Deviations
- recall — Class II2026-07-01
Presence of Foreign Substance.
- recall — Class II2025-03-26
Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
- recall — Class II2025-03-26
Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
- 4832025-03-13
No written record of investigation
- 4832025-03-13
Systems in place to comply with verification requirements
- 4832025-03-13
Acceptance of in-process materials
- 4832025-03-13
Procedures for sterile drug products
- recall — Class II2022-05-18
Defective container: loose crimp defect, potential loss of container integrity.
- 4832019-12-13
Cleaning SOP/inspection
- recall — Class II2017-09-27
Presence of particulate matter: glass flakes identified as lamellae observed during a routine quality inspection.
- recall — Class II2017-08-23
Presence of particulate matter: Visible glass flakes identified as lamellae in some drug product vials.
- recall — Class II2016-12-28
Lack of Assurance of Sterility: Potential cracks in glass vials
- warning_letter2014-01-27
FDA Warning Letter (drug product)
- recall — Class II2013-11-13
Presence of Particulate Matter: Visible cellulose fibers were observed in a small number of prefilled syringes during a routine quality examination.
- 4832012-12-12
Failure by applicant to report ADE
- 4832012-12-12
Failure to report post-marketing study ADEs
- 4832012-12-12
Failure to develop written procedures
- 4832012-12-12
Late submission of 15-day report
- 4832010-06-03
Late submission of 15-day report
Is this Amgen Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.